tbuckley/cabot-search huggingface dataset:
Reducing the Stress on Clinicians Working in the ICU
Authors: Jennifer B. Seaman, Taya R. Cohen, Douglas B. White
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective DPYD testing in colorectal cancer patients in a realworld UK population
Authors: B.K. Eccles, A.S. Harle, S. Pullinger, C. Holling, A. Ingram, S. Stark, M. Bunce, G. Melville, J. Gibbins, N. Calcutt, T. Hickish, M. Flubacher, T. Marinaki
Journal: Annals of Oncology (2018)
MA11.06 Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression
Authors: D. Ajona, M.J. Pajares, J. Freire, J. Gomez-Roman, E. Martinez-Terroba, S. Ortiz-Espinosa, A. Lledo, E. Arenas-Lazaro, J. Agorreta, F. Lecanda, L. Montuenga, R. Pio
Journal: Journal of Thoracic Oncology (2018)
P3.01-93 Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials
Authors: S. Swarup, K. Thein, S. Ball, M. Quirch, Y. Vorakunthada, A. Sultan, F. Hardwicke, L. Tijani, S. Awasthi
Journal: Journal of Thoracic Oncology (2018)
Involving underserved patient populations in research
Authors: Jeanine Suurmond, Marieke Torensma
Journal: BMJ (2018)

Wicks and colleagues argue that patient involvement in research is essential.1 We agree that ensuring diversity—so that the interests of well educated, white, middle class people do not dominate—is challenging. Patients from underserved groups are still excluded from scientific research. In many studies migrant patients are explicitly excluded because they do not speak the …
MA10.05 Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy
Authors: G. Fucà, M. Poggi, G. Galli, M. Imbimbo, G. Lo Russo, C. Proto, M. Vitali, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, D. Signorelli
Journal: Journal of Thoracic Oncology (2018)
A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Authors: A.-L. Cheng, C.-J. Yen, T. Okusaka, M. Ikeda, C.-H. Hsu, S.-Y. Wu, C. Morizane, Y. Hashimoto, K. Ueshima, T. Ohtomo, T. Tanaka, M. Kudo
Journal: Annals of Oncology (2018)
P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma
Authors: R. Taulli, L. Righi, F. Tabbò, F. Massa, A. D'Aveni, D. Morena, M.F. Lingua, A. Rigutto, F. Napoli, F. Picca, S. Novello, G. Scagliotti
Journal: Journal of Thoracic Oncology (2018)
P2.09-10 qRT-PCR as an Efficient and Reliable Diagnostic Screening Approach for the Detection of EML4-ALK Fusion Gene in NSCLC Samples: A Pilot Study
Authors: A. Choughule, V. Noronha, S. Banavali, P. Bagayatkar, K. Prabhash
Journal: Journal of Thoracic Oncology (2018)
3D Cell Printing of Perfusable Vascularized Human Skin Equivalent Composed of Epidermis, Dermis, and Hypodermis for Better Structural Recapitulation of Native Skin
Authors: Byoung Soo Kim, Ge Gao, Jae Yun Kim, Dong‐Woo Cho
Journal: Advanced Healthcare Materials (2018)

Although skin cell-printing has exhibited promises for fabrication of functional skin equivalents, existing skin models through 3D cell printing are still composed of dermal and epidermal layers. However, a key hope for printing skin is to improve structural complexity of human skin over conventional construction, enabling the precise localization of multiple cell types and biomaterials. Here, the complexity of skin anatomy is increased using 3D cell printing. A novel printing platform is suggested for engineering a matured perfusable vascularized 3D human skin equivalent composed of epidermis, dermis, and hypodermis. The skin model is evaluated using functional markers representing each region of epidermis, dermis, and hypodermis to confirm tissue maturation. It is hypothesized that the vascularized dermal and hypodermal compartments that provide a more realistic microenvironment can promote cross-talks with the epidermal compartment, producing better recapitulation of epidermal morphogenesis. Skin stemness in epithelial tissue is investigated. These findings reveal that the full-thickness skin has more similarities to the native human skin compared with the dermal and epidermal skin model, indicating that it better reflects the actual complexity of native human skin. It is envisioned that it offers better predictive and reliable in vitro platform for investigation of mechanisms of pathological research and skin disease modeling.
P3.01-103 Efficacy of Crizotinib in Chinese Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Multicenter Retrospective Study
Authors: S. Wang, P. Xing, D. Ma, Q. Wang, X. Hao, M. Wang, Y. Wang, L. Shan, T. Xin, L. Liang, H. Liang, Y. Du, Z. Zhang, J. Li
Journal: Journal of Thoracic Oncology (2018)
OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer
Authors: S. Lin, X. Lin, D. Clay, L. Yao, I. Mok, D. Gomez, J. Kurie, G. Simon, G. Blumenschein, J. Young, S. Phan, A. Sandler, V. Papadimitrakopoulou, J. Heymach, A. Tsao
Journal: Journal of Thoracic Oncology (2018)
Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
Authors: A. Krämer, F. Losa, L.M. Gay, D.R. Page, S. Foser, T.I. Mughal, J.S. Ross, G. Baciarello, L.R. Mileshkin, S. Osborne, H. Moch
Journal: Annals of Oncology (2018)
Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and human papilloma virus status in head and neck squamous cell carcinoma
Authors: S. Laban, G. Völkel, J. Ezic, T.K. Hoffmann, H.-G. Rammensee, J. Döscher, P.J. Schuler, C. Brunner, J. Kraus, H. Kestler
Journal: Annals of Oncology (2018)
Using MultiOmyx™ to analyze correlations between immunosuppressive cells and tumor-infiltrating lymphocytes in the pancreatic tumor microenvironment
Authors: A. Juncker-Jensen, J. Fang, J. Kuo, M.L. Nagy, R.K. Padmanabhan, E. Leones, F. Sahafi, S. Zhu, Q. Au, N. Hoe, J. William
Journal: Annals of Oncology (2018)
Tumor-specific activated photodynamic therapy with an oxidation-regulated strategy for enhancing anti-tumor efficacy
Authors: Huan Liang, Zhanwei Zhou, Renjie Luo, Mangmang Sang, Bowen Liu, Minjie Sun, Wei Qu, Feng Feng, Wenyuan Liu
Journal: Theranostics (2018)

Photodynamic therapy relies on photosensitizers to generate cytotoxic reactive oxygen species (ROS) resulting in the apoptois of tumor cells. However, there is an antioxidant system that impedes the elevation of oxidation levels in tumor cells. Thus, photodynamic therapy may exhibit insufficient curative effects due to ungenerous reactive oxygen species levels. Herein, we describe tumor-specific activated photodynamic therapy using an oxidation-regulating strategy. Methods: We first synthesised a reactive oxygen species-sensitive amphipathic prodrug of gambogic acid-grafted hyaluronic acid (HA-GA). The hydrophobic photosensitizer chlorin e6 (Ce6) was then loaded into HA-GA by hydrophobic interactions between GA and Ce6, forming amphipathic nanomicelles (HA-GA@Ce6). The ROS-responsive behavior, cytotoxicity, cell uptake, tumor cell killing, in vivo biodistribution and in vivo anti-tumor efficacy of HA-GA@Ce6 were investigated. The in vitro and in vivo experiments were performed on 4T1 murine breast cancer cells and 4T1 tumor model. Results: We validated that the micelles of HA-GA@Ce6 showed stronger cell uptake in 4T1 tumor cells and lower cytotoxicity in normal cells compared with free Ce6 and GA, which exhibited the benefits of nanomicelles on enhancing the tumor cell acumulation and reducing the side effects on normal cells synchronously. Additionally, the cytotoxic free radicals of photodynamic therapy were generated after irradiation and the high oxidation levels activated the ROS-sensitive GA prodrug efficiently, which killed the tumor cells and depleted intracellular glutathione (GSH), thereby impairing antioxidant levels and enhancing photodynamic therapy. Conclusion: With the successfully eradicated tumor growth in vivo. Our work represents a new photodynamic therapy concept, achieving superior anti-tumor efficacy by reducing intracellular antioxidant levels.
Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine: Should we continue doing it?
Authors: C. Avila Andrade, A.J. Cunquero Tomas, A.B. Fernandez Diaz, M. Meri Abad, L.D. Condori Farfan, I. Shaheen, S. Cervantes Garcia, M.J. Safont Aguilera, V. Iranzo Gonzalez-Cruz, V. Sforza, C. Caballero, M.C. Godes de Bremond, M. Gil, F.D.A. Aparisi Aparisi, A. Blasco Cordellat, A. Berrocal Jaime, I. Ferrer Bolufer, M. Lobo de Mena, G. Marcaida Benito, C. Camps
Journal: Annals of Oncology (2018)
P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
Authors: Y. Hu, Z. Liu, L. Wu, J. Cao, Z. Yang, C. Zhou, L. Cao, H. Wu, H. Shen, M. Jin, Y. Zhang, X. Mao, J. Xiang, K. Ma, B. Li, T. Zhang
Journal: Journal of Thoracic Oncology (2018)
P2.06-34 Inhibition of the HGF/c-Met Pathway for Malignant Mesothelioma with an Intra-Thoracic Injection of the NK4 Expressing Adenoviral Vectors
Authors: Y. Tada, T. Morinaga, I. Sekine, T. Suzuki, I. Shimomura, K. Tatsumi, Y. Takiguchi, H. Shimada, K. Hiroshima, M. Tagawa
Journal: Journal of Thoracic Oncology (2018)
Is There a Seasonal Influence on Cognition and Dementia?
Authors: Jennifer Abbasi
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In-depth assessment of metastatic prostate cancer with high tumour mutational burden
Authors: N. Mehra, J. van Riet, M. Smits, H. Westdorp, M. Gorris, T. van Ee, M. van der Doelen, I. van Oort, M. Sedelaar, J. Textor, E. Cuppen, K. Grunberg, M.J.L. Ligtenberg, W. Zwart, A. Bergman, H.J.G. van de Werken, J. Schalken, I.J.M. de Vries, M.P. Lolkema, W.R. Gerritsen
Journal: Annals of Oncology (2018)
OA04.07 Early Initiated Postoperative Rehabilitation Reduces Fatigue in Patients with Operable Lung Cancer: A Randomized Trial
Authors: M. Quist, M.S. Sommer, J. Vibe-Petersen, M. Stærkind Bohlbro, S. Langer, K. Larsen, K. Trier, M. Christensen, P. Clementsen, M. Missel, C. Henriksen, K. Poulsen, H. Langberg, J. Pedersen
Journal: Journal of Thoracic Oncology (2018)
EGFR amplification (amp) and survival in the REAL-3 trial
Authors: E. Smyth, K. Kouvelakis, D. Cunningham, J.C. Hahne, C. Peckitt, G. Vlachogiannis, D. Watkins, S. Rao, N. Starling, S.H. Wilson, T.S. Waddell, A. Okines, T. Crosby, W. Mansoor, J. Wadsley, G. Middleton, A. Wotherspoon, I. Chau, N. Valeri
Journal: Annals of Oncology (2018)
P3.01-26 A Framework for Systematic Clinical Evaluation of Technical Innovations in Lung Cancer Patients Treated on the MR-Linac (MRL)
Authors: D. Cobben, H. Bainbridge, J. Belderbos, P. Cheung, M. Dubec, D. Gomez, E. Gore, E. Knowles, F. Lalezari, U. Oelfke, J. Sonke, R. Tijssen, C. Van Es, M. Van Herk, A. Wetscherek, F. Mcdonald, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2018)
No effect of length time bias on the genomic risk in ER+ HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis
Authors: I. Gonzalez Barrallo, J.A. Perez Fidalgo, J. Ramirez, O. Burgues, J.V. Sorlí, O. Portoles, C. Hernando, D. Salas, A. Lluch
Journal: Annals of Oncology (2018)
Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment
Authors: Glenn J. Jaffe, C. Stephen Foster, Carlos E. Pavesio, Dario A. Paggiarino, Gerard E. Riedel
Journal: Ophthalmology (2018)

To assess the safety and efficacy of an intravitreal fluocinolone acetonide (FA) insert to manage inflammation associated with chronic noninfectious posterior uveitis.Multicenter, randomized, prospective, doubled-masked, sham-controlled, 3-year phase 3 clinical trial.One hundred twenty-nine participants with recurrent noninfectious posterior uveitis were assigned randomly to FA insert (n = 87) or sham injection (n = 42). The more severely affected eye in participants with bilateral disease was designated as the study eye.The insert (FA, 0.18 mg) was injected into the vitreous cavity; sham injection mimicked the insert delivery procedure. Ophthalmic examinations, OCT, and ocular tolerability and discomfort assessments were conducted; study visits were on days 7 and 28 and months 2, 3, 6, 9, and 12. Uveitis recurrence was treated as needed. The 6-month recurrence rate was the primary outcome measure.The 6-month (28% and 91%) and 12-month (38% and 98%) uveitis recurrence rates were significantly lower (P < 0.001) with FA insert vs. sham, respectively. Fewer recurrences per study eye (mean, 0.7 vs. 2.5), lower incidence of 15-letter or more decrease in best-corrected visual acuity (14% vs. 31%), and reduced systemic (19% vs. 40%) and local (7% vs. 62%) uveitis adjunctive treatments were observed with FA insert vs. sham, respectively. The FA insert group showed higher rates of cataract. Intraocular pressure-lowering treatment use was similar between groups. No deaths, treatment-related study discontinuations, or unanticipated safety signals were observed through 12 months.Chronic noninfectious posterior uveitis was managed successfully in this study population; FA insert eyes experienced fewer uveitis recurrence episodes, required fewer adjunctive treatments, and demonstrated less visual acuity loss compared with sham eyes. The FA insert treatment group showed higher rates of cataract; delivery by injection was not associated with an increase in ocular adverse events or any other safety measures not typically associated with local steroid use, suggesting the procedure is appropriate for an office setting.
PTH-008 Outcomes from an international multicentre hemospray registry
Authors: Durayd Alzoubaidi, Radu Rusu, Jason Dunn, Johannes W Rey, Shraddha Gulati, Bu’Hussain Hayee, Selena Dixon, Sulleman Moreea, Duncan Napier, John Anderson, Martin Dahan, Max Hu, Patricia Duarte, Phil Boger, Alberto Murino, Sina Jameie-Oskooei, Edward Despott, Cora Steinheber, Martin Goetz, Sharmila Subramaniam, Pradeep Bhandari, Laurence Lovat, Emmanuel Coron, Ralf Kiesslich, Rehan Haidry
Journal: Endoscopy (2018)

<h3>Introduction</h3> Acute gastrointestinal bleeding (AGIB) carries poor outcomes unless prompt endoscopic haemostasis is achieved. Hemospray is a novel intervention that creates a mechanical barrier over bleeding sites when applied endoscopically. Primary aim of this <b>international prospective multicentre registry</b> is to collect outcomes of patients with AGIB after endoscopic Hemospary application. Secondary outcomes of rebleeding, disease and procedure specific outcomes are also collected. <h3>Method</h3> Prospective data (Jan2016-Jan2018) from 11 centres across UK, France and Germany collected. Hemospray used as mono therapy, dual-therapy with standard haemostatic techniques or rescue therapy once standard methods failed. Immediate haemostasis defined as cessation of bleeding within 5 min after application of Hemospray. Rebleeding defined as subsequent drop in Hb (&gt;2 g/L), haematemesis, persistent melaena with haemodynamic compromise post therapy. <h3>Results</h3> 275 cases recruited worldwide(203 M and 72 F). Median pretreatment Blatchford score (BS) 11 for all cases. 246 patients (89%) achieved immediate haemostasis after endoscopic therapy with Hemospray (table 1). Similar haemostasis rates noted in the Hemospray monotherapy (<b>92</b><b>%</b>), combination therapy (<b>90</b><b>%</b>) and rescue therapy (<b>85</b><b>%</b>) group. Peptic ulcer bleed was the most common pathology (53%) and forrest Ib the most common lesion type (66%). 29 patients did not achieve immediate haemostasis.Median BS was higher in this group at 13 (IQR 11–16, p&lt;0.05). Forrest Ib was the most common lesion type in this group (76%, p&lt;0.05). 28 cases of rebleeding reported after successful haemostasis. The median BS in these was higher at 13 (IQR 10.25–14.75, p&lt;0.05). Forrest Ib was the most common bleed in this group (50%, p&lt;0.05). <h3>Conclusion</h3> These data show high rates of immediate haemostasis (89%). Forrest Type 1b lesions have a higher rate of unsuccessful haemostais and increased risk of rebleeding after therapy. Patients with rebleeding and unsuccessful treatment had higher BS at baseline. The expansion of this international registry will provide data on the efficacy of Hemospray in various disease and patient types over the coming years.
Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay
Authors: P. Vitazka, N. Tikoo, A. Balasubramanyam, L. Xi, S. Yaung, E. Kwok, A. Lovejoy, D. Klass, M. Heibeck, K. Probst, A. Rehfeldt, E. Meldgaard, A. Madsen, M. Clement, J. Palma, B. Sorensen, P. Meldgaard
Journal: Annals of Oncology (2018)
Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
Authors: C. Montagut, V. Alonso, P. Escudero, C. Fernández-Martos, A. Salud Salvia, M. Méndez, J. Gallego Plazas, J.R. Rodriguez, M. Martín-Richard, J. Fernández-Plana, J. Aparicio, J. Feliu Batlle, X. García de Albéniz, F. Rojo, V. Fernández, B. Claes, G.G. Maertens, E. Sablon, B.A.W. Jacobs, J. Maurel
Journal: Annals of Oncology (2018)
Clinical implication of PDL1 expression and TILs in male breast cancer: More hype or new hope? Results from the UMBREAC trial (NCT03240510)
Authors: S. Abdeljaoued, I. Bettaieb, A. Goucha, O. Adouni, H. El Mokh, H. Bouzaiene, J. Ben Hassouna, H. Boussen, K. Rahal, A. Gamoudi
Journal: Annals of Oncology (2018)
P2.11-17 MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer
Authors: B. Pattnaik, S. Chakraborty, P. Bajpai, A. Agrawal, R. Guleria, A. Mohan
Journal: Journal of Thoracic Oncology (2018)
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501–9
Authors: Christian Gratzke, Emad Siddiqui
Journal: European Urology (2018)
The importance of comorbidity assessment in patients with oral squamous cell carcinoma (OSCC): Could the adult comorbidity evaluation – 27 (ACE-27) provide an additional information?
Authors: U.M. Jariod Ferrer, S. Blanco Sanfrutos, M.A. Gavin Clavero, T. Uson Bouthelier, B. Nadal Cristobal, I. Moral Saez, I. Pajares Bernad, A.I. Cisneros Gimeno, J. Martinez Trufero
Journal: Annals of Oncology (2018)
P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients with Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Authors: D. Radosavljevic, J. Spasic, M. Ristic, V. Nikolic, N. Nikolic, N. Stanic, F. Djordjevic, D. Gavrilovic
Journal: Journal of Thoracic Oncology (2018)
Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis
Authors: S. Gillessen, S. Schmid, H. Beltran, D.V.P. Almeida, N. Mehra, P. Lavaud, R. Morales Barrera, D. Pignataro, E. Castro Marcos, V. Conteduca, E. Efstathiou, H.M.L. Le, C.V. Pezaro, H. Suzuki, A. Zivi, D. Klingbiel, A.G. Omlin
Journal: Annals of Oncology (2018)
Circulating tumor DNA by next generation sequencing as a prognostic and predictive biomarker in metastatic colorectal cancer
Authors: N. Jia, L. Chang, X. Dou, M. Guan, Y. Shao, N. Li, Y. Cheng, H. Ying, Z. Sun, Y. Zhou, L. Zhao, J. Zhou, C. Bai
Journal: Annals of Oncology (2018)
P2.06-36 EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
Authors: J. Raskin, V. Surmont, B. Hasan, E. De Maio, P. Van Schil, J. Van Meerbeeck
Journal: Journal of Thoracic Oncology (2018)
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment
Authors: A.R. Clamp, I.A. McNeish, A. Dean, D. Gallardo-Rincon, J.-W. Kim, D.M. O’Donnell, J. Hook, S. Blagden, J.D. Brenton, R. Naik, T.J. Perren, S. Sundar, A.D. Cook, E.C. James, H. Gabra, R. Lord, M. Hall, G. Dark, R.S. Kaplan, J.A. Ledermann
Journal: Annals of Oncology (2018)
Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study
Authors: R. Laeufle, D. Arnold, S. Kopetz, J. Straub, R. Bruns, G. Massimini, R. Debenedetto, R. Linke, E. Elez Fernandez, J. Tabernero
Journal: Annals of Oncology (2018)
The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer
Authors: S.T. Langkjer, J. Kenholm, J.D. Jensen, K. Wedervang, A.T. Brixen, M. Grunnet, L. Stenbygaard, H. Danø, V. Glavicic, E.H. Jacobsen, A.S. Brems-Eskildsen, H.L. Kruse, T. Dongsgaard, J. Neimann, J. Geisler
Journal: Annals of Oncology (2018)